Comparative Pharmacology
Head-to-head clinical analysis: OXYTOCIN 10 USP UNITS IN DEXTROSE 5 versus OXYTOCIN 5 USP UNITS IN DEXTROSE 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OXYTOCIN 10 USP UNITS IN DEXTROSE 5 versus OXYTOCIN 5 USP UNITS IN DEXTROSE 5.
OXYTOCIN 10 USP UNITS IN DEXTROSE 5% vs OXYTOCIN 5 USP UNITS IN DEXTROSE 5%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Increases intracellular calcium in uterine myofibrils, stimulating contractions. Binds to oxytocin receptors in myometrium and mammary glands.
Oxytocin is a nonapeptide hormone that binds to oxytocin receptors on the myometrium, increasing intracellular calcium and stimulating uterine smooth muscle contraction. It also acts on mammary gland myoepithelial cells to promote milk ejection.
IV infusion: 0.5-2 mU/min, increased by 1-2 mU/min every 30-60 min until desired uterine activity, then reduce; max 20 mU/min.
Induction or augmentation of labor: IV infusion, initial rate 0.5-2 mU/min, increased by 1-2 mU/min every 15-30 min until adequate contractions; max 20 mU/min. Postpartum hemorrhage: IV infusion 10-40 units in 1000 mL D5W or NS, rate adjusted to control bleeding.
None Documented
None Documented
Terminal half-life: 1-6 minutes (IV); clinical effect ceases rapidly after infusion stops due to rapid clearance.
Terminal elimination half-life: 1–6 minutes (intravenous); 2–5 minutes (intramuscular); short half-life requires continuous infusion for sustained effect.
Renal: >99% as unchanged drug; <1% hepatic metabolism and biliary excretion.
Renal (primarily); >99% of infused oxytocin is excreted unchanged in urine; negligible biliary/fecal elimination.
Category C
Category C
Oxytocic
Oxytocic